<DOC>
	<DOCNO>NCT00492999</DOCNO>
	<brief_summary>RATIONALE : Hepatic arterial infusion use catheter carry tumor-killing substance directly liver . Drugs use chemotherapy work different way stop growth tumor cell , either kill cell stop divide . Giving floxuridine dexamethasone directly arteries around tumor together combination chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well hepatic arterial infusion floxuridine dexamethasone work give together combination chemotherapy treat patient colorectal cancer spread liver .</brief_summary>
	<brief_title>Hepatic Arterial Infusion With Floxuridine Dexamethasone Combined With Combination Chemotherapy Treating Patients With Colorectal Cancer That Has Spread Liver</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess rate conversion complete resection patient initially unresectable colorectal cancer metastatic liver treat hepatic arterial infusion comprise floxuridine dexamethasone combination systemic irinotecan hydrochloride either oxaliplatin leucovorin calcium/fluorouracil . Secondary - Evaluate time progression patient treat regimen . - Evaluate disease-free survival patient treat regimen . - Evaluate overall survival patient treat regimen . - Determine response rate ( complete , partial , moderate response ) patient treat regimen . - Evaluate safety profile tolerability regimen patient . - Assess expression pattern VEGF receptor VEGFR1 , VEGFR2 , VEGFR3 cognate ligand ( i.e. , VEGF-A , VEGF-B , VEGF-C , VEGF-D , P1GF ) patient treat regimen . - Correlate circulating angiogenic marker tumor resectability , disease progression , patient survival . - Procure normal diseased liver tissue evaluation thymidylate synthase , p53 gene , p21 , topoisomerase 1 , dihydropyrimidine dehydrogenase , excision repair cross-complementing gene level . - Assess expression pattern tissue factor ( TF ) explore correlation TF receptor PAR-1 , PAR-2 , TF regulator PTEN , k-ras , b- raf , p53 , outcome . ( Closed 11/30/10 ) - Assess prognostic predictive role preoperative , pretreatment , treatment serum TF regard outcome ( progression-free survival overall survival ) response treatment regimen salvage treatment EGFR-inhibitors . ( Closed 11/30/10 ) OUTLINE : This open-label , nonrandomized study . Patients assign 1 2 treatment group accord receipt 2 prior course oxaliplatin ( vs yes ) . - Group 1 ( 2 prior course oxaliplatin ) : Patients receive hepatic arterial infusion ( HAI ) therapy comprise floxuridine dexamethasone continuously day 1-14 . Patients also receive oxaliplatin IV 2 hour irinotecan hydrochloride IV 30 minute day 1 15 . Courses repeat every 4 week absence disease progression unacceptable toxicity . - Group 2 ( 2 prior course oxaliplatin ) : Patients receive HAI therapy group 1 . Patients also receive irinotecan hydrochloride IV 30 minute leucovorin calcium IV 30 minute day 1 15 fluorouracil IV continuously 48 hour day 1 , 2 , 15 , 16 . Courses repeat every 4 week absence disease progression unacceptable toxicity . In group , patient may undergo complete resection liver metastases completion least 3 course therapy . Some patient undergo blood tissue collection periodically correlative immunological study . Samples analyze VEGF receptor VEGFR1 , VEGFR2 , VEGFR3 , thymidylate synthase , p53 , p21 , topoisomerase 1 , dihydropyrimidine dehydrogenase , excision repair cross-complementing gene level . After completion study treatment , patient follow every 3 month 2 year , every 4 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal adenocarcinoma metastatic liver Previously treat untreated disease No clinical radiographic evidence extrahepatic disease Primary tumor may present study registration provide obstruct intestinal lumen significantly bleed If present , primary tumor resect time pump placement Must inoperable liver metastasis confirm 23 hepatobiliary surgeon assign radiologist Liver metastases &lt; 70 % liver parenchyma Inoperable liver metastasis define one following : More 6 metastasis single lobe one lesion ≥ 5 cm At least 6 metastasis distribute diffusely lobes liver When marginnegative resection would require resection three hepatic vein , portal vein , retrohepatic vena cava Requires resection leave &lt; 2 hepatic segment ( include caudate lobe ) behind adequate arterial portal inflow , venous outflow , biliary drainage No ascites hepatic encephalopathy No history primary CNS tumor PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % WBC ≥ 3,000/mm^3 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 INR &lt; 1.5 Hemoglobin ≥ 9 g/dL Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Physically able tolerate major partial hepatectomy No active infection No concurrent active malignancy , except potentially resectable primary colorectal tumor No bleeding diathesis coagulopathy No history serious systemic disease , include follow : Myocardial infarction within past 6 month Uncontrolled hypertension ( i.e. , blood pressure &gt; 150/100 mm Hg medication ) Unstable angina New York Heart Association class IIIV congestive heart failure Unstable symptomatic arrhythmia require medication Chronic atrial arrhythmia ( i.e. , atrial fibrillation paroxysmal supraventricular tachycardia ) allow Peripheral vascular disease ≥ grade 2 No serious nonhealing active wound , ulcer , bone fracture No history seizure well control standard medical therapy No stroke transient ischemic attack within past 6 month No concurrent obstruction gastrointestinal genitourinary tract PRIOR CONCURRENT THERAPY : At least 4 week since prior radiotherapy pelvis Prior chemotherapy allow No prior radiotherapy , hepatic thermal ablation , resection ( biopsy ) liver No prior floxuridine No prior hepatic arterial infusion No concurrent chronic aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication know inhibit platelet function No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>liver metastasis</keyword>
</DOC>